PCM
STRO icon

Pentwater Capital Management’s Sutro Biopharma STRO Stock Holding History

Pentwater Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,000
Closed -$1.13M – 165
2022
Q4 		$1.13M Buy
+14,000
New +$973K 0.02% 96

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Pentwater Capital Management's STRO Position: Q1 2024 in Review

Pentwater Capital Management sold out of Sutro Biopharma (STRO) in Q1 2024, closing a stake of 45,000 shares — an estimated $1.93M sold.

Pentwater Capital Management first reported a position in STRO in Q3 2018 and held it in 22 quarters. The position peaked at $6.18M in Q4 2020. 117 funds tracked by Wall St. Rank hold STRO as of Q1 2024.

  • Pentwater Capital Management reported no remaining Sutro Biopharma position as of Q1 2024 after selling out during the quarter.
  • Pentwater Capital Management sold 45,000 Sutro Biopharma shares in Q1 2024, an estimated $1.93M.
  • Pentwater Capital Management first reported a position in Sutro Biopharma in Q3 2018 and held it in 22 quarters.
  • Pentwater Capital Management's Sutro Biopharma position peaked at $6.18M in Q4 2020.
  • 117 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2024.

Based on Pentwater Capital Management's 13F filing for Q1 2024, filed 15 May 2024.